Previous 10 | Next 10 |
NextCure (NASDAQ: NXTC ): Q1 GAAP EPS of $0.33 beats by $0.77 . More news on: NextCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
BELTSVILLE, Md., May 07, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today reported first quarter 2020 ...
BELTSVILLE, Md., May 06, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will pres...
Alnylam Pharmaceuticals Receives $2 Billion Funding from Blackstone Alnylam Pharmaceuticals ( ALNY ) announced that Blackstone Group (BX) has decided to invest up to $2 billion through a combination of debt and equity. The funding will impart the much-needed liquidity to the company and wi...
On Monday, clinical-stage biopharmaceutical company NextCure (NASDAQ: NXTC) announced that it would be delaying the start of upcoming phases of clinical trials for two immuno-oncology drug candidates, NC318 and NC410. "The COVID-19 pandemic has put significant strain on our cli...
NextCure (NASDAQ: NXTC ) provides following updates on its clinical trial activities due to the impact of the COVID-19 pandemic. More news on: NextCure, Inc., Healthcare stocks news, Read more ...
BELTSVILLE, Md., April 13, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided an update on the ...
BELTSVILLE, Md., April 08, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will pre...
BELTSVILLE, Md., March 30, 2020 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment ...
Compugen (NASDAQ: CGEN ) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up 9% premarket. More news on: Compugen Ltd., Incyte Corporation, NextCure, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
BELTSVILLE, Md., June 20, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies, today announced that it will present and host institutional investor meetings...
Of the evaluable ICI-naïve MSS/MSI-L CRC patients without liver metastasis, there were 2 confirmed ongoing PRs and a disease control rate of 51% Of the 7 evaluable ovarian cancer patients, there were 3 PRs and a disease control rate of 43% Data to be presented June 1, 2024,...
Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to fund operations into second half of 2026 BELTSVILLE...